|
|
|
Volumn 108, Issue 4, 2011, Pages 255-259
|
|
New therapies for hepatitis C virus infection.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA2B INTERFERON;
ANTIVIRUS AGENT;
DRUG DERIVATIVE;
IL28B PROTEIN, HUMAN;
INTERLEUKIN DERIVATIVE;
MACROGOL DERIVATIVE;
N (3 AMINO 1 (CYCLOBUTYLMETHYL) 2,3 DIOXOPROPYL) 3 (2 ((((1,1 DIMETHYLETHYL)AMINO)CARBONYL)AMINO) 3,3 DIMETHYL 1 OXOBUTYL) 6,6 DIMETHYL 3 AZABICYCLO(3.1.0)HEXAN 2 CARBOXAMIDE;
N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE;
OLIGOPEPTIDE;
PEGINTERFERON ALPHA2B;
PROLINE;
RIBAVIRIN;
TELAPREVIR;
ARTICLE;
DRUG COMBINATION;
GENETIC POLYMORPHISM;
GENETICS;
HEALTH;
HEPATITIS C;
HUMAN;
PHARMACOGENETICS;
ANTIVIRAL AGENTS;
DRUG THERAPY, COMBINATION;
HEPATITIS C, CHRONIC;
HUMANS;
INTERFERON ALFA-2B;
INTERLEUKINS;
OLIGOPEPTIDES;
PHARMACOGENETICS;
POLYETHYLENE GLYCOLS;
POLYMORPHISM, GENETIC;
PROLINE;
RIBAVIRIN;
WORLD HEALTH;
|
|
EID: 80054783511
PISSN: 00266620
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (8)
|
|
References (0)
|
